“Get Ready for a Game-Changing Merger: Alumis and ACELYRIN Join Forces to Revolutionize Immune-mediated Disease Treatment!”

Welcome to the Wonderful World of Clinical Trials! Exciting Updates from Alumis Pharmaceuticals Phase 3 ONWARD Trials for ESK-001 Alumis Pharmaceuticals is making waves in the medical world with their groundbreaking Phase 3 ONWARD trials for ESK-001 in moderate-to-severe plaque psoriasis. The company has recently announced that the topline data for these trials is on…

Read More

Net2Phone’s New AI Agent: Your Tech-Savvy, Polite, and Humorous Sidekick for Business Communications!

Meet Your New Best Friend: Net2phone AI Agent, Your 24/7 Customer Experience Guru Imagine having a helpful, efficient, and charming assistant who’s always there for you, day or night, ready to manage your sales, support, and administrative tasks. Well, meet Net2phone AI Agent, your new best friend and the ultimate multitasker! Your Personal Assistant, Anytime,…

Read More

Decoding Deleveraging: Bitcoin Market’s Latest Trend and Its Impact on Investors

Massive Bitcoin Liquidations: A New Opportunity for Investors In the ever-volatile world of cryptocurrencies, market fluctuations can be both exciting and daunting for investors. One such event that has piqued the interest of many is the recent massive liquidations in Bitcoin’s open interest, as reported by the data analytics platform CryptoQuant. This occurrence has historically…

Read More

Unlocking Success: The Power of Accessing Information Online

Levi & Korsinsky Investigates Flux Power Holdings, Inc. for Securities Law Violations Investigation Initiated NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Flux Power Holdings, Inc. (“Flux Power Holdings, Inc.”) (NASDAQ:FLUX) concerning possible violations of federal securities laws. Financial Statements Restatement…

Read More

Breaking Down the Numbers: Total PCE Inflation Inches Towards Fed’s 2% Target by 2024

U.S. Consumer Inflation Approaches 2% Target What the Numbers Say In September 2024, U.S. consumer inflation moved closer to the Federal Reserve’s target of 2% as year-on-year total Personal Consumption Expenditure (PCE) inflation dropped to 2.1%. While total PCE inflation slowed down, core PCE inflation, which excludes volatile food and energy prices, remained steady at…

Read More